The following criteria is provided for health care professionals.

Inclusion Criteria:

Screening:

• Patients with histologically confirmed Multiple Myeloma that could be eligible for high dose chemotherapy and autologous stem cell transplant in the future will be considered. Patients must have a bone marrow biopsy available, or one scheduled to be performed for a clinical indication. (Patients that have been treated with an induction regimen are eligible for this phase of study).

Treatment:

• Patients enrolled in screening phase of study.
• Expression of survivin in plasma cells by immunohistochemistry.
• Patients planned for treatment with high dose melphalan and autologous hematopoietic cell transplant (HCT).
• Complete blood count (CBC) with an absolute neutrophil count (ANC) >= 1,000/uL, hemoglobin >= 8.0 g/dL and platelet count >= 50,000/uL.
• Liver enzymes: total bilirubin less than or equal to 2 mg/dL (>2 mg/dL permitted if the patient has evidence of Gilbert's disease based upon prior bilirubin elevation or genetic testing); Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) less than 1.5 X the upper limit of normal (ULN).
• Signed informed consent form in accordance with institutional and federal law policies.

Exclusion Criteria:

Treatment:

• Patients with Complete Response (CR) or stringent CR after induction therapy as defined by International Response Criteria after most recent therapy.
• Patients with progressive disease at time of transplant.
• Pregnant or lactating woman (as evaluated by serum testing within 48 hours of administration of the first vaccine in women of child bearing potential).
• HIV infection confirmed by nucleic acid tests (NAT).
• Common variable immunodeficiency.
• Active central nervous system (CNS) malignancy.
• Active bacterial, fungal or viral infection.
• Prior history of allogeneic hematopoietic cell transplantation
• Prior malignancy within 5 years of enrollment excluding non-melanoma skin cancer or cervical carcinoma after curative resection, not requiring chemotherapy.
• History of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria-toxoid containing vaccine.